Long COVIDSYNPOCovNCT05610436
Post-Covid Condition Cohort: Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors
An observational study of Long COVID and Post-Acute COVID-19, run by Central Hospital, Nancy, France at 1 site in France.
Trial summary
The aim of our cohort is to collect prospectively, in a standardized and exhaustive manner, the health data of patients referred to the CAPCoV, our holistic referal post covid clinics for post-covid condition in order to be able to identify typical profiles of patients suffering from post covid syndrome and to follow… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Long COVID, Post-Acute COVID-19, Post-Acute COVID19 Syndrome
- How many people
- 500 participants
- Where
- 1 siteFrance
- Study dates
- 7 Jan 2022to Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: outpatients treated in the Nancy University Hospital Long Covid Support and Care Center for post-Covid condition according to WHO definition
Who may be able to join
- outpatients treated in the Nancy University Hospital Long Covid Support and Care Center for post-Covid condition according to WHO definition
Who cannot join
- patient opposing the processing for research purposes of their data collected in routine care for their care
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Nancy University Hospital
Vandœuvre-lès-Nancy, Grand Est, 54511
Francois GOEHRINGER, MD, +33383154097, francois.goehringer@chru-nancy.fr
About this study
Official title: Post-Covid Condition Monitoring Cohort: Evaluation of the Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors
The aim of our cohort is to collect prospectively, in a standardized and exhaustive manner, the health data of patients referred to the CAPCoV, our holistic referal post covid clinics for post-covid condition in order to be able to identify typical profiles of patients suffering from post covid syndrome and to follow the evolution of their disease over time.
- Conditions
- Long COVID, Post-Acute COVID-19, Post-Acute COVID19 Syndrome
- Medical subject headings
- Post-Acute COVID-19 Syndrome
What is being measured
The primary outcome is the main question the study is designed to answer.
Symptoms
Symptoms collected in a standardized manner during consultations, their persistence over time, their evolution (improvement, stagnation, worsening) and their severity (mild, moderate, severe)
Measured: every 6 months up to 3 years
Secondary outcomes (6)
Medical history
Measured: baseline
fatigue
Chalder scale: range 0 to 33, >22/33 classified severe
Measured: every 6 months up to 3 years
Dyspnea
mMRC
Measured: every 6 months up to 3 years
Cognitive impairement
Montréal Cognitive Assessment : range 0 to 30, <26/30 classified pathologic
Measured: every 6 months up to 3 years
inappropriate hyperventilation syndrome
Nijmegen score: range 0 to 64, >23/34 classified "possible inapropriate hyperventilation" syndrome"
Measured: every 6 months up to 3 years
additional examinations
Biology, imaging
Measured: every 6 months up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2022
- Study start7 Jan 2022
- Primary completionDec 2025 (estimated)
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- More trials run by Central Hospital, Nancy, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, GOEHRINGER François, Central Hospital, Nancy, France
- Investigators
- Francois GOEHRINGER, MD, Principal investigator, Infectious Diseases Department, Nancy University Hospital,F-54000 Nancy, France.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05610436
- Sponsor's protocol ID
- 2022PI148
- Acronym
- SYNPOCov
- Status last verified
- Oct 2022
- First submitted
- 20 Oct 2022
- Last updated
- 9 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Post-Covid Condition Monitoring Cohort: Evaluation of the Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors
- ClinicalTrials.gov ID
- NCT05610436
- Acronym / sponsor ID
- SYNPOCov / 2022PI148
- Conditions
- Long COVID, Post-Acute COVID-19, Post-Acute COVID19 Syndrome
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- 7 Jan 2022 (actual)
- Primary completion
- Dec 2025 (estimated)
- Study completion
- Jun 2026 (estimated)
- First posted
- 9 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of our cohort is to collect prospectively, in a standardized and exhaustive manner, the health data of patients referred to the CAPCoV, our holistic referal post covid clinics for post-covid condition in order to be able to identify typical profiles of patients suffering from post covid syndrome and to follow the evolution of their disease over time.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- outpatients treated in the Nancy University Hospital Long Covid Support and Care Center for post-Covid condition according to WHO definition
Key inclusion criteria (1 listed)
- outpatients treated in the Nancy University Hospital Long Covid Support and Care Center for post-Covid condition according to WHO definition
Key exclusion criteria (1 listed)
- patient opposing the processing for research purposes of their data collected in routine care for their care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Symptoms
Time frame: every 6 months up to 3 years
Symptoms collected in a standardized manner during consultations, their persistence over time, their evolution (improvement, stagnation, worsening) and their severity (mild, moderate, severe)
6 secondary outcomes
Medical history
Time frame: baseline
fatigue
Time frame: every 6 months up to 3 years
Dyspnea
Time frame: every 6 months up to 3 years
Cognitive impairement
Time frame: every 6 months up to 3 years
inappropriate hyperventilation syndrome
Time frame: every 6 months up to 3 years
additional examinations
Time frame: every 6 months up to 3 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2022.
Related trials for Long COVID
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
Active, not recruiting
Long COVID Brain Fog: Cognitive Rehabilitation Trial
Long COVID, Brain Fog
RecruitingPhase 2
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
Post-acute Sequelae of COVID-19, Long COVID
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Francois GOEHRINGER, MD principal investigator
Infectious Diseases Department, Nancy University Hospital,F-54000 Nancy, France.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Long COVID and Post-Acute COVID-19, run by Central Hospital, Nancy, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Francois GOEHRINGER, MD (+33383154097, francois.goehringer@chru-nancy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Symptoms (time frame: every 6 months up to 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2022; AzTrials last refreshed its copy on 7 Nov 2026.